Every few years the weight loss field produces a number that stops people mid scroll. This time it is 24.2%, and then, in a larger trial, 28.3%. Those are average percentages of total body weight lost, and they are the largest figures the obesity drug field has produced.
The molecule behind them is called retatrutide, and the shorthand for what makes it different is "triple agonist". It is also, as things stand, licensed precisely nowhere. That gap between the results and the legal position is why it has become one of the most counterfeited substances in the UK, and why it is worth understanding properly rather than through whatever a social media account is claiming this week.
What a triple agonist actually is
An agonist is a molecule that switches a receptor on. The current generation of weight loss medicines works by switching on gut hormone receptors that regulate appetite and blood sugar. The difference between the drugs is simply how many of those receptors each one reaches.
| Medicine | Receptors it activates | Class | UK licence |
|---|---|---|---|
| Semaglutide (Wegovy, Ozempic) | GLP-1 | Mono-agonist | Licensed |
| Tirzepatide (Mounjaro) | GLP-1 and GIP | Dual agonist | Licensed for weight management since November 2023 |
| Retatrutide | GLP-1, GIP and glucagon | Triple agonist | None, anywhere in the world |
The third receptor is the whole story. GLP-1 and GIP activation mainly reduce how much you eat. Glucagon receptor activation does something different: in the founding pharmacology work, the researchers described weight loss being augmented by glucagon driven increases in energy expenditure on top of the appetite reduction from the other two. In plain terms, it works on both sides of the energy balance rather than one.
Structurally it is a 39 amino acid peptide with a fatty diacid chain attached to slow its clearance. That gives it a half-life of about six days, which is what makes a once weekly injection possible.
What the trials have actually found
There is a real evidence base here, and it is worth separating the part that has been through peer review from the part that has not.
The peer-reviewed anchor is a Phase 2 trial of 338 adults with obesity, published in the New England Journal of Medicine in 2023. Over 48 weeks, the highest dose group lost 24.2% of body weight against 2.1% on placebo. In that same arm, 83% of participants lost at least 15% of their body weight and 26% lost at least 30%. A prespecified substudy of participants with fatty liver found MRI-measured liver fat fell by up to 86% at 48 weeks.
The Phase 3 figures are larger, and they carry a caveat that matters. In TRIUMPH-1, a trial of more than 2,300 adults over 80 weeks, the manufacturer reported 28.3% average weight loss on the highest dose against 2.2% on placebo, with 45.3% of that group losing at least 30% of their body weight. A 104 week extension in participants who started with a BMI of 35 or above reached 30.3%.
The caveat: those Phase 3 numbers exist as company press releases and conference presentations. They have not been published in a peer-reviewed journal, and no regulator has yet assessed them. That is not an accusation of dishonesty, it is a statement about what stage the evidence is at. Treat a press release figure as a claim awaiting scrutiny, not as a finding.
The side effect profile follows the pattern you would expect, and gets steeper with dose. In TRIUMPH-1, nausea affected 42.4% on the top dose against 14.8% on placebo, and 11.3% of that group stopped treatment because of side effects. In the knee osteoarthritis trial, discontinuation on the top dose reached 18.2%. One signal is distinctive: dysesthesia, meaning odd or unpleasant skin sensations, affected up to 20.9% of the highest dose group against 0.7% on placebo, which is not a prominent feature of the licensed medicines. The peer-reviewed Phase 2 data also recorded cardiac arrhythmias in 6% of participants overall, reaching 14% in one arm against 3% on placebo.
Where UK approval actually stands
This is the part most articles get wrong, usually by accident.
Retatrutide holds no marketing authorisation in any country in the world. Not the UK, not the EU, not the United States. The MHRA's own position is that it "has not been approved for UK use". The FDA states that it and similar compounds "have not been found safe and effective for any condition".
There is one document on the MHRA's public register, and it gets misread constantly. It is a paediatric investigation plan, agreed in June 2026, with a completion date of November 2035. A paediatric investigation plan is an obligation to study a drug in children as part of its development. It is not an approval, not a licence, and not a signal that availability is close. Anywhere you see "the MHRA has agreed a plan" presented as progress toward the pharmacy shelf, that is what is being misdescribed.
As for timing: the manufacturer said in July 2026 that it intends to submit a United States application in the first quarter of 2027, pushed back from an earlier expectation while it compiles manufacturing data. No UK application is on public record. Any site quoting a specific UK launch year is guessing.
Trials have run at UK sites, including Birmingham, Glasgow, Liverpool, Sheffield, Leicester and Aberdeen, and a large cardiovascular outcomes trial is not due to complete until around February 2029. Most are closed to recruitment.
What is still unknown
Worth being clear about, because the headline percentage crowds it out:
- No completed head-to-head trial against a licensed medicine. The comparison against tirzepatide, TRIUMPH-5, has not reported, and neither has the comparison against semaglutide. Comparing percentages across separate trials with different populations and durations is not evidence of superiority.
- No established cardiovascular benefit. In the trial of people with severe obesity and established heart disease, the event rate differences were not statistically significant. The dedicated outcomes trial completes around 2029.
- No clinical liver outcomes. An 86% fall in liver fat is an imaging measurement, not proof of reversed liver disease.
- Nothing beyond 104 weeks, and nothing yet on what happens to weight after stopping.
The counterfeit problem, which is not hypothetical
Because there is demand and no legal supply, an illicit one has appeared, and it has been industrial in scale.
Since October 2025 the MHRA has dismantled three illicit UK manufacturing sites: a facility in Northampton with more than 2,000 doses awaiting dispatch, a farm near Sleaford, and a country estate near Northampton where around 12,000 doses were seized and two men were arrested on suspicion of offences under the Human Medicines Regulations 2012. The regulator's summary of the risk is that these products are "untested, unauthorised, and potentially deadly", that some "may even be contaminated with toxic substances", and that seized medicines can contain too much or too little of the declared ingredient, or other harmful ingredients entirely.
The reporting on buyers is worse than the seizure figures. A Channel 4 News investigation covered by The Independent found the product sold openly on Facebook and TikTok, with a seller falsely claiming it came from a pharmacy and giving conflicting dosing instructions. One woman described losing vision in one eye after using a copied weight loss drug bought through social media.
The escalation protocols used in the trials make the point neatly. Participants started at 2 mg and stepped up every four weeks, and even then the fastest escalating arm in Phase 2 recorded the highest nausea rate in the whole study. A vial bought from a messaging app arrives with none of that, and frequently with no instructions at all.
What to do while you wait
If a medicine is the right tool for you, licensed ones exist, and they are prescribed after an assessment by somebody accountable for the decision. Our comparisons of fat freezing and tirzepatide and the oral semaglutide tablet cover what the licensed routes actually involve, and if you are trying to work out where you sit clinically, our guide to BMI is a sensible place to start. It is also worth reading why weight loss is genuinely harder for some people before concluding that the answer has to be pharmacological.
And if the thing bothering you is a specific pocket of fat rather than your weight overall, that is a different problem with a different answer. Fat freezing reduces fat in a treated area and changes shape. It is not a weight loss treatment, most people see no change on the scale, and we would rather say so than let you assume otherwise.
The triple agonist may well earn its licence. When it does, it will arrive through a pharmacy, with a leaflet, a prescriber and a route for reporting side effects. Until then, the only version available to you is one nobody has checked.
If you would like an honest assessment of which option, if any, suits you, book a free consultation and we will tell you straight.
The triple agonist, honestly assessed
What the evidence genuinely shows
- In a peer-reviewed Phase 2 trial, participants on the highest dose lost 24.2% of their body weight over 48 weeks, against 2.1% on placebo
- A prespecified substudy found MRI-measured liver fat fell by up to 86% at 48 weeks, which is a striking result for an imaging biomarker
- The mechanism is genuinely different from the licensed medicines, adding a third receptor that raises energy expenditure rather than only suppressing appetite
What it does not show
- It holds no marketing authorisation in any country in the world, so no regulator has assessed its safety, its quality or how it is manufactured
- Most of the headline Phase 3 figures exist only as manufacturer press releases and have not been peer reviewed
- Side effects rise steeply with dose: nausea reached 42.4% and up to 18.2% of participants stopped treatment because of adverse events
- No head-to-head trial against a licensed medicine has reported, so nobody can say it is better than what is already available
Frequently Asked Questions
What does triple agonist mean?
An agonist is a molecule that switches a receptor on. Semaglutide switches on one receptor, GLP-1. Tirzepatide switches on two, GLP-1 and GIP. A triple agonist switches on three, adding the glucagon receptor, which in laboratory work increases energy expenditure rather than simply reducing appetite. It is a single molecule doing all three jobs, not three drugs combined.
Is the triple agonist approved in the UK?
No. Retatrutide, the drug in question, holds no marketing authorisation in the UK, the European Union, the United States, or anywhere else. The MHRA states that it has not been approved for UK use. The only file on the MHRA's public register is a paediatric investigation plan, which is a development obligation agreed with the regulator and is not an approval or a sign of imminent availability.
When will it be available?
Nobody can honestly tell you. The manufacturer said in July 2026 that it intends to file a United States application in the first quarter of 2027, having pushed that back from an earlier expectation. No UK marketing authorisation application appears in public records at all. Any specific UK launch date you see quoted is guesswork, and it is usually being quoted by a site that wants to sell you something now.
Can I join a trial to get it?
Several trials have run at UK sites, including in Birmingham, Glasgow, Liverpool, Sheffield and Aberdeen, but most are now closed to recruitment. The manufacturer has also opened a narrow expanded access programme for adults with refractory obesity and at least two serious obesity related complications who cannot join a trial. Both routes are controlled by the sponsor, and neither is something a clinic can arrange for you.
What about the versions being sold online?
Treat them as dangerous. The MHRA has dismantled three illicit UK factories since October 2025 and made arrests, and says products sold here claiming to contain retatrutide are likely to be illegal and potentially dangerous to health. Seized products have been found to contain too much or too little of the declared ingredient, or other harmful ingredients entirely. There is no way for a buyer to know which.
